About
About Angion Biomedica Corp
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.
Visit company website
5 years, 4 months ago
From a valuation standpoint, the stock is 87.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 169.8.
Based on the above factors, Angion Biomedica Corp. Common Stock gets an overall score of 1/5.